Literature DB >> 20959885

Safe retrieval of embolized patent ductus arteriosus coil via left thoracotomy.

Melanie Finkbeiner1, Jacques Leblanc, Martin Hosking, Andrew Campbell.   

Abstract

During transcatheter occlusion of a patent ductus arteriosus, one potential complication is that the coil can embolize into one of the branch pulmonary arteries or the aorta. It is often possible to remove this coil percutaneously, but at times, surgical intervention is required. The present report describes a case in which the coil migrated to the left pulmonary artery and repeated attempts to retrieve the coil were unsuccessful. A left thoracotomy was performed, the coil was removed and the patent ductus arteriosus was ligated.

Entities:  

Keywords:  Cardiac catheterization; Congenital heart disease (CHD); Pediatric; Pulmonary embolism; Thoracotomy

Year:  2010        PMID: 20959885      PMCID: PMC2954034     

Source DB:  PubMed          Journal:  Exp Clin Cardiol        ISSN: 1205-6626


  5 in total

1.  Coil entrapment in the tricuspid valve apparatus requiring surgical removal: an unusual complication of transcatheter closure of patent ductus arteriosus.

Authors:  M C Fulwani; B Vajifdar; A G Tendolkar; B V Dalvi
Journal:  Indian Heart J       Date:  1999 Jan-Feb

2.  Transcatheter occlusion of persistent arterial duct. Report of The European Registry.

Authors: 
Journal:  Lancet       Date:  1992-10-31       Impact factor: 79.321

Review 3.  Transcatheter closure of the patent ductus arteriosus.

Authors:  Ronald G Grifka
Journal:  Catheter Cardiovasc Interv       Date:  2004-04       Impact factor: 2.692

4.  Problems encountered during introduction of Gianturco coils for transcatheter occlusion of the patent arterial duct.

Authors:  O Galal; M de Moor; F Fadley; S Qureshi; S Naffa; S Oufi; M Suhl; F Abbag; A A Schmaltz
Journal:  Eur Heart J       Date:  1997-04       Impact factor: 29.983

5.  Advantages and disadvantages of coils for transcatheter closure of patent ductus arteriosus.

Authors:  M Omar Galal
Journal:  J Interv Cardiol       Date:  2003-04       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.